Cartesian Therapeutics Inc
RNAC7.550USD
-0.120-1.56%
Cierre 11/06, 16:00（ET）Cotizaciones retrasadas 15 min
196.30MCap. mercado
PérdidaP/E TTM
Más Datos de Cartesian Therapeutics Inc Compañía
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Información de Cartesian Therapeutics Inc
Símbolo de cotizaciónRNAC
Nombre de la empresaCartesian Therapeutics Inc
Fecha de salida a bolsaJun 22, 2016
Director ejecutivoDr. Carsten Brunn, Ph.D.
Número de empleados66
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 22
Dirección7495 New Horizon Way
CiudadFREDERICK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal21703
Teléfono13013488698
Sitio Webhttps://www.cartesiantherapeutics.com/
Símbolo de cotizaciónRNAC
Fecha de salida a bolsaJun 22, 2016
Director ejecutivoDr. Carsten Brunn, Ph.D.
Ejecutivos de Cartesian Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
3.82K
-14.03%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
--
-100.00%
Dr. Michael S. Singer, M.D., Ph.D.
Dr. Michael S. Singer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
3.82K
-14.03%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 14 de ago
Actualizado: jue., 14 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Springer Timothy A
33.22%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.98%
Singer (Michael S.)
2.72%
MPM BioImpact LLC
2.64%
Otro
34.93%
Accionistas
Accionistas
Proporción
Springer Timothy A
33.22%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.98%
Singer (Michael S.)
2.72%
MPM BioImpact LLC
2.64%
Otro
34.93%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
39.87%
Corporation
20.04%
Investment Advisor
17.88%
Investment Advisor/Hedge Fund
5.51%
Hedge Fund
1.66%
Research Firm
0.24%
Insurance Company
0.08%
Bank and Trust
0.05%
Pension Fund
0.03%
Otro
14.64%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
181
6.62M
25.45%
-1.00M
2025Q2
206
22.27M
85.81%
-1.28M
2025Q1
226
22.94M
90.08%
+138.68K
2024Q4
230
22.26M
88.90%
-105.22K
2024Q3
229
20.22M
92.77%
+6.58M
2024Q2
235
14.41M
85.20%
+9.02M
2024Q1
233
3.74M
346.71%
-1.42M
2023Q4
240
3.82M
71.00%
-922.87K
2023Q3
251
3.63M
70.60%
-1.17M
2023Q2
261
3.72M
72.70%
-649.68K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Springer Timothy A
8.64M
33.22%
+22.36K
+0.26%
Apr 14, 2025
Seven One Eight Three Four Irrevocable Trust
4.56M
17.52%
--
--
Apr 14, 2025
Fidelity Management & Research Company LLC
2.33M
8.98%
-5.79K
-0.25%
Jun 30, 2025
Singer (Michael S.)
707.06K
2.72%
-623.00
-0.09%
Apr 14, 2025
MPM BioImpact LLC
686.01K
2.64%
-104.77K
-13.25%
Jun 30, 2025
TAS Partners, L.L.C.
656.51K
2.52%
+126.72K
+23.92%
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
582.03K
2.24%
-26.00K
-4.28%
Jun 30, 2025
Invus Public Equities Advisors, LLC
563.27K
2.17%
--
--
Jun 30, 2025
Kalayoglu (Murat)
502.42K
1.93%
-8.88K
-1.74%
Apr 14, 2025
The Vanguard Group, Inc.
496.37K
1.91%
-7.17K
-1.42%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: hace 23 horas
Actualizado: hace 23 horas
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Proshares Ultra Russell 2000
0%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.72%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
iShares Micro-Cap ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
ALPS Medical Breakthroughs ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Fecha
Tipo
Relación
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
